Prevalence and intensity of Onchocerca volvulus infection and efficacy of ivermectin in endemic communities in Ghana: a two-phase epidemiological study

Lancet

Volumn 369, Issue 9578, 2007, Pages 2021-2029

  Osei Atweneboana, Mike Y ^a,d   Eng, Jeffrey KL ^a   Boakye, Daniel A ^b   Gyapong, John O ^c,e   Prichard, Roger K ^a  

^a MCGILL UNIVERSITY   (Canada)

^b University of Ghana   (Ghana)

^c Health Research Unit Ghana Health Service   (Ghana)

^d West African Science Service Centre on Climate Change and Adapted Land Use   (Ghana)

^e Ochocerciasis Control Programme of Ghana   (Ghana)

Author keywords

[No Author keywords available]

Indexed keywords

IVERMECTIN;

ADULT; AGED; ARTICLE; DRUG EFFICACY; DRUG MECHANISM; HUMAN; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MICROFILARIA (NEMATODE LARVA); ONCHOCERCA VOLVULUS; ONCHOCERCIASIS; PARASITE TRANSMISSION; PRIORITY JOURNAL;

EID: 34250196496     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)60942-8     Document Type: Article

References (32)

1. World Health Organization. Onchocerciasis and its control: Report of a WHO Expert Committee on Onchocerciasis Control 1995. Technical Report Series No. 852. Geneva: WHO.
2. Basanez M., Pion S., Churcher T., et al. River blindness: asuccess story under threat?. PLoS Med 3 (2006) 1454-1460
3. Borsboom G., Boatin B., Nagelkerke N., et al. Impact of ivermectin on onchocerciasis transmission: assessing the empirical evidence that repeated ivermectin mass treatments may lead to elimination/eradication in West-Africa. Filaria J 2 (2003) 1-25
4. Awadzi K., Dadzie K., Schulz-Key H., Haddock D., Gilles H., and Aziz M. The chemotherapy of onchocerciasis X. An assessment of four single doses treatment regimes of MK-933 (ivermectin) in human onchocerciasis. Ann Trop Med Parasitol 79 (1985) 63-67
5. Awadzi K., Dadzie K., Klager S., and Gilles H. The chemotherapy of onchocerciasis. XIII. Studies with ivermectin in onchocerciasis patients in northern Ghana, a region with long lasting vector control. Ann Trop Med Parasitol 40 (1989) 361-366
6. Duke B., Zeaflores G., Castro J., Cupp E., and Munoz B. Effects of 3-month doses of ivermectin on adult Onchocerca volvulus. Am J Trop Med Hyg 46 (1992) 189-194
7. Alley E., Plaisier A., Boatin B., et al. The impact of five years of annual ivermectin treatment on skin microfilarial loads in the onchocerciasis focus of Asubende, Ghana. Trans R Soc Trop Med Hyg 88 (1994) 581-584
8. Greene B., Taylor H., Cupp E., et al. Comparism of ivermectin and diethylcarbamazine in the treatment of onchocerciasis. N Engl J Med 313 (1985) 133-138
9. Schulz-Key H., and Karam M. Periodic reproduction of Onchocerca volvulus. Parasitol Today 2 (1986) 284-286
10. Boatin B., Hougard J., Alley E., et al. The impact of Mectizan on the transmission of onchocerciasis. Ann Trop Med Parasitol 92 suppl 1 (1998) 46-60
11. Awadzi K., Boakye D., Edwards G., et al. An investigation of persistent microfilaridermias despite multiple treatments with ivermectin, in two onchocerciasis-endemic foci in Ghana. Ann Trop Med Parasitol 98 (2004) 231-249
12. Awadzi K., Attah S., Addy E., et al. Thirty-month follow-up of sub-optimal responders to multiple treatments with ivermectin, in two onchocerciasis-endemic foci in Ghana. Ann Trop Med Parasitol 98 (2004) 359-370
13. Eng J., and Prichard R. A comparison of genetic polymorphism in populations of Onchocerca volvulus from untreated- and ivermectin-treated patients. Mol Biochem Parasitol 142 (2005) 193-202
14. Ardelli B., and Prichard R. Identification of variant ABC-transporter genes among Onchocerca volvulus collected from ivermectin-treated and untreated patients in Ghana, West Africa. Ann Trop Med Parasitol 98 (2004) 371-384
15. Ardelli B., Guerriero S., and Prichard R. Genomic organization and effects of ivermectin selection on Onchocerca volvulus P-glycoprotein. Mol Biochem Parasitol 143 (2005) 58-66
16. Ardelli B., Guerriero S., and Prichard R. Ivermectin imposes selection pressure on P-glycoprotein from Onchocerca volvulus: linkage disequilibrium and genotype diversity. Parasitology 132 (2006) 375-386
17. Ardelli B., Guerriero S., and Prichard R. Characterization of a half-size ATP-binding cassette transporter gene which may be a useful marker for ivermectin selection in Onchocerca volvulus. Mol Biochem Parasitol 145 (2006) 94-100
18. Wolstenholme A., Fairweather I., Prichard R., von Samson-Himmelstjerna G., and Sangster N. Drug resistance in veterinary helminths. Trends Parasitol 20 (2004) 469-476
19. Remme J., Ba O., Dadzie K., and Karam M. A force of infection model for onchocerciasis and its applications in the epidemiological evaluation of the Onchocerciasis Control Programme in the Volta River Basin area. Bull World Health Organ 64 (1986) 667-681
20. Ministry of Health, Ghana. Onchocerciasis control activities in Ghana. Annual report. 2000: 1-6.
21. Awadzi K., Opoku N., Addy E., and Quartey B. The chemotherapy of onchocerciasis. XIX: The clinical and laboratory tolerance of high dose ivermectin. Trop Med Parasitol 46 (1995) 131-137
22. Remme J., DeSole G., Dadzie K., et al. Large scale ivermectin distribution and its epidemiological consequences. Acta Leidensia 59 (1990) 177-191
23. Chavasse D., Post R., Lemoh P., and Whitworth J. The effect of repeated doses of ivermectin on adult female Onchocerca volvulus in Sierra Leone. Trop Med Parasitol 43 (1992) 256-262
24. Plaisier A., Alley E., Boatin B., et al. Irreversible effects of ivermectin on adult parasites in onchocerciasis patients in the Onchocerciasis Control Programme in West Africa. J Infect Dis 172 (1995) 204-210
25. Ali M., Mukhtar M., Baraka O., Homeida M., Kheir M., and Mackenzie C. Immunocompetence may be important in the effectiveness of Mectizan (ivermectin) in the treatment of human onchocerciasis. Acta Trop 84 (2002) 49-53
26. Whitworth J., Maude G., and Downham M. Clinical and Parasitological responses after up to 6·5 years of ivermectin treatment for onchocerciasis. Trop Med Int Health 1 (1996) 786-793
27. WHO. Summary report of the OCP/TDR meeting on the impact of ivermectin on onchocerciasis transmission (2001), World Health Organization, Rotterdam
28. Eng J., Blackhall W., Osei-Atweneboana M., et al. Ivermectin selection on B-tubulin: evidence in Onchocerca volvulus and Haemonchus contortus. Mol Biochem Parasitol 150 (2006) 229-235
29. Lustigman S., James E., Tawe W., and Abraham D. Towards a recombinant antigen vaccine against Onchocerca volvulus. Trends Parasitol 18 (2002) 135-141
30. Nutman T. Future directions for vaccine-related onchocerciasis research. Trends Parasitol 18 (2002) 237-239
31. Peter J., Hotez P., and Ferris M. The antipoverty vaccines. Vaccine 24 (2006) 5787-5799
32. Hoerauf A., Mand S., Adjei O., Fleischer B., and Büttner D. Depletion of Wolbachia endobacteria in Onchocerca volvulus by doxycycline and microfilaridermia after ivermectin treatment. Lancet 357 (2001) 1415-1416